Samarth Kulkarni Sells 27,154 Shares of CRISPR THERAPTC (CRSP) Stock
CRISPR THERAPTC (NASDAQ:CRSP) insider Samarth Kulkarni sold 27,154 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total transaction of $545,252.32. Following the completion of the transaction, the insider now owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
CRISPR THERAPTC (NASDAQ CRSP) opened at 20.48 on Friday. The firm’s 50-day moving average is $18.17 and its 200-day moving average is $17.74. CRISPR THERAPTC has a 1-year low of $11.63 and a 1-year high of $25.00. The company’s market capitalization is $831.30 million.
CRISPR THERAPTC (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.06. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. The business’s quarterly revenue was up 350.0% compared to the same quarter last year. Equities research analysts predict that CRISPR THERAPTC will post ($2.43) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/01/samarth-kulkarni-sells-27154-shares-of-crispr-theraptc-crsp-stock.html.
Several research analysts have recently weighed in on the stock. Cann assumed coverage on shares of CRISPR THERAPTC in a research note on Monday, July 17th. They issued a “market perform” rating for the company. Chardan Capital restated a “buy” rating on shares of CRISPR THERAPTC in a research note on Monday, August 14th. SunTrust Banks, Inc. assumed coverage on shares of CRISPR THERAPTC in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research note on Tuesday, July 18th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. CRISPR THERAPTC presently has an average rating of “Buy” and an average target price of $21.92.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Wellington Management Group LLP boosted its stake in shares of CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares in the last quarter. IHT Wealth Management LLC purchased a new stake in shares of CRISPR THERAPTC during the first quarter valued at $110,000. Wells Fargo & Company MN boosted its stake in shares of CRISPR THERAPTC by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of CRISPR THERAPTC during the second quarter valued at $206,000. Finally, Monashee Investment Management LLC boosted its stake in shares of CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. 23.90% of the stock is owned by institutional investors and hedge funds.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related stocks with our FREE daily email newsletter.